Evidence map›Paper›PMID 34471971›Full record

ArticleActa neurologica Belgica2022

Preliminary validation of the apraxia battery for adults-second edition (ABA-2) in Greek patients with dementia.

Georgios Papadopoulos, Dimitrios Parissis, Eleni Konstantinopoulou, Konstantinos Natsis, Anna Gotzamani-Psarrakou, Panagiotis Ioannidis

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neurologica Belgica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Georgios PapadopoulosSecond Department of Neurology, AHEPA University Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece. papgeo82@gmail.com.ORCID http://orcid.org/0000-0002-5387-062X
Dimitrios ParissisSecond Department of Neurology, AHEPA University Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0003-4300-2826
Eleni KonstantinopoulouSecond Department of Neurology, AHEPA University Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Konstantinos NatsisSecond Department of Neurology, AHEPA University Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Anna Gotzamani-PsarrakouSecond Department of Neurology, AHEPA University Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Panagiotis IoannidisSecond Department of Neurology, AHEPA University Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0003-0254-6624

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundApraxia is considered a supportive feature in Alzheimer's disease (AD) patients. It has been reported that patients with frontotemporal dementia (FTD) may present apraxia, especially in the buccofacial area. The Apraxia Battery for Adults (ABA-2) is a brief and practical battery for praxis impairment and has been validated in Greek post-stroke patients.

aimTo validate and evaluate ABA-2 test, translated and culturally adapted, in a sample of Greek demented patients. PATIENTS AND

methodsPatients diagnosed with FTD (n = 20) and AD (n = 20) were included in the study. Age-, gender-, and education- matched healthy controls (n = 20) were also tested. All participants completed Adenbrooke's Cognitive Examination-Revised (ACE-R), Frontal Rating Scale (FRS), Frontal Behavioral Inventory (FBI), and ABA-2 battery. Sensitivity and specificity of ABA-2 were calculated, as well as its consistency and statistical significance for diagnosing apraxia.

resultsThe ABA-2 was able to differentiate demented patients from healthy controls with a sensitivity of 77.5% and specificity of 95%. Its validity was confirmed with Cronbach's alpha coefficient > 0.7, indicating satisfactory internal reliability. Statistically significant differences were found when comparing total ABA-2 score (p < 0.0001), as well as 3 out of 6 subtests of ABA-2, between the two study groups. Age, gender and education were not correlated with ABA-2 score.

conclusionABA-2 is a valid, reliable and sensitive battery to differentiate demented patients from healthy individuals in the Greek population. We propose the modification of ABA-2 to a 5-subtest tool, to be administered as a bed-side test.

Indexed as

Alzheimer DiseaseApraxiasFrontotemporal DementiaAdultGreeceHumansNeuropsychological TestsReproducibility of ResultsABA-2Alzheimer’s diseaseApraxiaFrontotemporal dementia

Identifiers

PMID34471971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.